npj Breast Cancer

Papers
(The median citation count of npj Breast Cancer is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
International survey on invasive lobular breast cancer identifies priority research questions341
Author Correction: Characterization and spatial distribution of infiltrating lymphocytes in medullary, and lymphocyte-predominant triple negative breast cancers178
Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancer172
C/EBPβ isoform-specific regulation of migration and invasion in triple-negative breast cancer cells158
Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?144
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients128
GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer102
Biological correlates associated with high-risk breast cancer patients identified using a computational method95
Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer93
The impact of lymphedema on health-related quality of life up to 10 years after breast cancer treatment89
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab74
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors70
IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women68
Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer67
Immunotherapy for early triple negative breast cancer: research agenda for the next decade67
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab65
The clinical and molecular significance associated with STING signaling in breast cancer65
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment59
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models55
Circulating tumor DNA validity and potential uses in metastatic breast cancer54
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays54
Loss of the extracellular matrix glycoprotein EMILIN1 accelerates Δ16HER2-driven breast cancer initiation in mice51
International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01)51
Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer47
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC45
Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer44
Survival outcomes after omission of surgery for ductal carcinoma in situ44
Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer42
Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer42
Baseline gut microbiome alpha diversity predicts chemotherapy-induced gastrointestinal symptoms in patients with breast cancer42
Temporal evolution of breast cancer brain metastases treatments and outcomes41
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases40
Overweight and prognosis in triple-negative breast cancer patients: a systematic review and meta-analysis39
Effectiveness of the Korean National Cancer Screening Program in reducing breast cancer mortality38
Is conservative management of ductal carcinoma in situ risky?38
The cytosolic iron–sulfur cluster assembly (CIA) pathway is required for replication stress tolerance of cancer cells to Chk1 and ATR inhibitors38
Deep learning radiomics based prediction of axillary lymph node metastasis in breast cancer38
Understanding metastasis mixed-treatment responses through genomic analyses36
Kataegis in clinical and molecular subgroups of primary breast cancer35
Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer34
Breast cancer clinical trial participation among diverse patients at a comprehensive cancer center32
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer32
Cancer risk assessment of premalignant breast tissues from patients with BRCA mutations by genome profiling32
Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program31
Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment31
Ductal keratin 15+ luminal progenitors in normal breast exhibit a basal-like breast cancer transcriptomic signature31
ZNF92, an unexplored transcription factor with remarkably distinct breast cancer over-expression associated with prognosis and cell-of-origin30
How can artificial intelligence models assist PD-L1 expression scoring in breast cancer: results of multi-institutional ring studies30
Radiation recall dermatitis following letrozole administration in patient with a remote history of radiation therapy30
Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer29
Computational pathology improves risk stratification of a multi-gene assay for early stage ER+ breast cancer29
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study29
ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance28
GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer28
Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies28
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models28
Large language model (ChatGPT) as a support tool for breast tumor board27
Oncogene-mediated metabolic gene signature predicts breast cancer outcome27
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer27
Cook and Move for Your Life, an eHealth intervention for women with breast cancer26
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy26
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer26
A systematic review of determinants of breast cancer risk among women with benign breast disease25
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled 25
Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies25
Sentinel node involvement with or without completion axillary lymph node dissection: treatment and pathologic results of randomized SERC trial25
Trigger point injection for post-mastectomy pain: a simple intervention with high rate of long-term relief25
PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer25
Risk of primary lung cancer after adjuvant radiotherapy in breast cancer—a large population-based study25
Randomized trial of weight loss on circulating ghrelin levels among breast cancer survivors25
Interrogating breast cancer heterogeneity using single and pooled circulating tumor cell analysis24
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers24
A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer24
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models24
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer24
Prognostic value of structural variants in early breast cancer patients24
The 21-gene recurrence score in early non-ductal breast cancer: a National Cancer Database analysis24
Interaction between CD36 and FABP4 modulates adipocyte-induced fatty acid import and metabolism in breast cancer23
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer23
Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases22
Subclonal heterogeneity and evolution in breast cancer22
Increased trunk fat is associated with altered gene expression in breast tissue of normal weight women22
Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer21
Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy21
ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation21
Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence21
Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study21
MRI background parenchymal enhancement, breast density and breast cancer risk factors: A cross-sectional study in pre- and post-menopausal women20
Signaling of MK2 sustains robust AP1 activity for triple negative breast cancer tumorigenesis through direct phosphorylation of JAB120
Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study20
CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape20
Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer20
Therapeutic and immunomodulatory potential of pazopanib in malignant phyllodes tumor20
Development and validation of a clinical breast cancer tool for accurate prediction of recurrence19
Gene signatures in patients with early breast cancer and relapse despite pathologic complete response19
Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer19
Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study19
Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer19
Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry19
Assessment of MRI to estimate metastatic dissemination risk and prometastatic effects of chemotherapy18
Plasma extracellular vesicle long RNA profiles in the diagnosis and prediction of treatment response for breast cancer18
Plasma C-peptide mammographic features and risk of breast cancer18
Racial discrimination among women seeking breast cancer care18
Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib17
Long non-coding RNA MIR200CHG promotes breast cancer proliferation, invasion, and drug resistance by interacting with and stabilizing YB-117
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer17
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer17
Artificial intelligence in breast pathology – dawn of a new era17
Post-diagnosis weight trajectories and mortality among women with breast cancer17
The different prognostic significance of polysialic acid and CD56 expression in tumor cells and lymphocytes identified in breast cancer17
Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial16
Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer16
Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination16
Survival benefit of platinum-based regimen in early stage triple negative breast cancer: A meta-analysis of randomized controlled trials16
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer16
Immunologically “cold” triple negative breast cancers engraft at a higher rate in patient derived xenografts16
Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer16
Breast Cancer Consensus Subtypes: A system for subtyping breast cancer tumors based on gene expression16
Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer15
Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer15
MammOnc-DB, an integrative breast cancer data analysis platform for target discovery15
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer15
Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings15
Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer15
Author Correction: Defining features of hereditary lobular breast cancer due to CDH1 with magnetic resonance imaging and tumor characteristics15
Predicting early breast cancer recurrence from histopathological images in the Carolina Breast Cancer Study15
The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer14
Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancer14
Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy14
Computerized cognitive training improves cognitive function in primary breast cancer survivors14
Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers14
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer14
Crown-like structures in breast adipose tissue of breast cancer patients: associations with CD68 expression, obesity, metabolic factors and prognosis14
Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patients14
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials14
Author Correction: Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR14
Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study14
The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment14
An updated PREDICT breast cancer prognostic model including the benefits and harms of radiotherapy14
An emerging generation of endocrine therapies in breast cancer: a clinical perspective14
Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2/N0 HER2+ breast cancer14
Co-targeting of metabolism using dietary and pharmacologic approaches reduces breast cancer metastatic burden13
Mcam stabilizes a luminal progenitor-like breast cancer cell state via Ck2 control and Src/Akt/Stat3 attenuation13
The deubiquitinating enzyme USP4 regulates BRCA1 stability and function13
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers13
Multi-center study on predicting breast cancer lymph node status from core needle biopsy specimens using multi-modal and multi-instance deep learning13
Mortality after second malignancy in breast cancer survivors compared to a first primary cancer: a nationwide longitudinal cohort study13
PROCURE European consensus on breast cancer multigene signatures in early breast cancer management13
Immunoarchitectural patterns as potential prognostic factors for invasive ductal breast cancer13
Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer13
Breast cancer survivors’ opinion on personalizing endocrine therapy and developing informative tools13
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer13
Spatial proximity of CD8+ T cells to tumor cells predicts neoadjuvant therapy efficacy in breast cancer13
High-dimensional immune cell profiling of cerebrospinal fluid from patients with metastatic breast cancer and leptomeningeal disease13
De-escalation in breast cancer surgery13
A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer13
Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition13
Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients13
Spatial interplay of tissue hypoxia and T-cell regulation in ductal carcinoma in situ12
Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer12
Automated and rapid detection of cancer in suspicious axillary lymph nodes in patients with breast cancer12
Automated quantification of levels of breast terminal duct lobular (TDLU) involution using deep learning12
Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial12
Bone mineral density in women newly diagnosed with breast cancer: a prospective cohort study12
Hyperleptinemia in obese state renders luminal breast cancers refractory to tamoxifen by coordinating a crosstalk between Med1, miR205 and ErbB12
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade12
Improving the odds together: a framework for breast cancer research scientists to include patient advocates in their research12
The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study11
Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer11
Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis11
Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab11
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis11
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer11
Author Correction: Upregulation of lipid metabolism genes in the breast prior to cancer diagnosis11
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer11
Optimal adjuvant therapy in older (≥70 years of age) women with low-risk early-stage breast cancer11
SPP1+ macrophages in HR+ breast cancer are associated with tumor-infiltrating lymphocytes11
Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer11
Allostatic load as a predictor of postoperative complications in patients with breast cancer10
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer10
MicroRNA-200c restoration reveals a cytokine profile to enhance M1 macrophage polarization in breast cancer10
IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer10
Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial10
High GPER expression in triple-negative breast cancer is linked to pro-metastatic pathways and predicts poor patient outcomes10
MUC1-C dependency in drug resistant HR+/HER2− breast cancer identifies a new target for antibody-drug conjugate treatment10
Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study10
Endoplasmic reticulum stress inhibits AR expression via the PERK/eIF2α/ATF4 pathway in luminal androgen receptor triple-negative breast cancer and prostate cancer10
Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial10
Effects of RARα ligand binding domain mutations on breast fibroepithelial tumor function and signaling10
High prevalence of somatic PIK3CA and TP53 pathogenic variants in the normal mammary gland tissue of sporadic breast cancer patients revealed by duplex sequencing10
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2– breast cancer (LEADER)10
Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations10
Solid-basaloid variant of adenoid cystic carcinoma of the breast with near complete response to neoadjuvant chemotherapy10
Acupuncture versus cognitive behavioral therapy for pain among cancer survivors with insomnia: an exploratory analysis of a randomized clinical trial10
Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients9
Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America9
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer9
Iminodibenzyl induced redirected COX-2 activity inhibits breast cancer progression9
Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer9
Impact of body mass index in therapeutic response for HER2 positive breast cancer treated with neoadjuvant targeted therapy: a multi-center study and meta-analysis9
Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib9
The impact of reproductive factors on DNA methylation-based telomere length in healthy breast tissue9
CBD-oil as a potential solution in case of severe tamoxifen-related side effects9
Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy9
High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer9
Author Correction: Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer9
Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancer9
LINC00355 regulates p27KIP expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer9
Establishment and characterization of immortalized human breast cancer cell lines from breast cancer patient-derived xenografts (PDX)9
Immunotherapy in breast cancer: an overview of current strategies and perspectives9
Mammographic texture features associated with contralateral breast cancer in the WECARE Study9
Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets9
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC9
Clinical outcomes in estrogen receptor-positive early-stage breast cancer patients with Recurrence Score 26-30: observational real-world cohort study9
Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer9
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer9
Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer8
Breast cancer dormancy is associated with a 4NG1 state and not senescence8
Clonal heterogeneity in ER+ breast cancer reveals the proteasome and PKC as potential therapeutic targets8
Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis8
The Breast Cancer Classifier refines molecular breast cancer classification to delineate the HER2-low subtype8
Ductal carcinoma in situ: a risk prediction model for the underestimation of invasive breast cancer8
Calcifications in triple-negative breast cancer: Molecular features and treatment strategies8
Altered ribosomal profile in acquired resistance and reversal associates with pathological response to chemotherapy in inflammatory breast cancer8
Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness8
The LINC01119-SOCS5 axis as a critical theranostic in triple-negative breast cancer8
Impact of a randomized weight loss trial on breast tissue markers in breast cancer survivors8
Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models8
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy8
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models8
Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial8
Dose dense doxorubicin plus cyclophosphamide in a modified KEYNOTE522 regimen for triple negative breast cancer7
Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ7
Clinico-pathological factors predicting pathological response in early triple-negative breast cancer7
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer7
Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer7
Circulating tumor cells in breast cancer: clinical validity and utility7
Immune landscape of breast tumors with low and intermediate estrogen receptor expression7
Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 405027
A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN)7
Current gene panels account for nearly all homologous recombination repair-associated multiple-case breast cancer families7
Reversion of breast epithelial polarity alterations caused by obesity7
Clinical relevance of pathogenic germline variants in mismatch repair genes in Chinese breast cancer patients7
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)7
Integrative multiomics-histopathology analysis for breast cancer classification7
Triple negative breast cancer: Pitfalls and progress7
Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer7
PI3K/AKT signaling activates HIF1α to modulate the biological effects of invasive breast cancer with microcalcification7
0.091659069061279